Tim Morris most recently served as the Chief Financial Officer of Opthea, Limited (NASDAQ: OPT, ASX: OPT) until October, 2023. Previously he served as Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. from 2020 to 2022. He was on the Board of Directors at Humanigen from 2016 to 2020, where he was chairman of the audit committee and a member of the compensation committee. He was the Chief Financial Officer of Iovance Biotherapeutics, Inc. from 2017 to 2020. Mr. Morris has extensive Board experience, currently serving as a board member of DBV Technologies (NASDAQ: DBVT, Euronext: DBV.PA), where he serves as chairman of the audit committee and a member of the pricing committee; Univercells S.A., where he is chairman of the audit committee and a member of the strategic committee; and Humanetics Corporation, where he serves as the chair of the audit committee and a member of the compensation committee. Mr. Morris earned a BS in Business, with an emphasis in accounting, from California State University and is a Certified Public Accountant (inactive). Our Board believes that Mr. Morris’ extensive board experience and company oversight experience, along with his strong finance and management background, qualifies him to serve on our Board of Directors.